Introduction
Vasculogenesis and angiogenesis are the processes responsible for the development of the circulatory system, the first functional unit in the developing embryo (1) . Postnatal angiogenesis is encountered in pathologic situations such as diabetic retinopathy, arthritis, and, most notably, tumor growth and metastasis. It is also involved in therapeutic angiogenesis: the development of collateral blood vessels supplying ischemic tissues, either endogenously or in response to administration of growth factors.
Therapeutic Angiogenesis
Angiogenesis is defined as the extension of the primitive vasculature through sprouting of new capillaries from the pre-existing network. It is a complex process that includes activation, migration, and proliferation of endothelial cells (2) . The therapeutic implications of angiogenic growth factors were identified by the pioneering work of Folkman and colleagues over two decades ago (3) . Their work documented the extent to which tumor development was dependent upon neovascularization and suggested that this relationship might involve angiogenic growth factors that were specific for neoplasms. More recent investigations have established the feasibility of using recombinant formulations of such angiogenic growth factors to expedite and/or augment collateral artery development in animal models of myocardial and hindlimb ischemia. This novel strategy for the treatment of vascular 
Therapeutic Angiogenesis Achieved by Recombinant Protein Administration
The angiogenic growth factors first employed for the purpose of therapeutic angiogenesis comprised members of the fibroblast growth factor (FGF) family. Baffour et al. administered bFGF in daily intramuscular (IM) doses of 1 or 3 jig to rabbits with acute hindlimb ischemia; at the completion of 14 days of treatment, angiography and necropsy measurement of capillary density showed evidence of augmented collateral vessels in the lower limb, compared with controls (5). Pu et al. used aFGF to treat rabbits in which the acute effects of surgically induced hindlimb ischemia were allowed to subside for 10 days before beginning a 10-day course of daily 4-mg IM injections; at the completion of 30 days follow-up, both angiographic and hemodynamic evidence of collateral development was superior to that in ischemic controls treated with IM saline (6). Yanagisawa-Miwa et al. likewise demonstrated the feasibility of bFGF for salvage of infarcted myocardium, but in this case growth factor was administered intra-arterially at the time of coronary occlusion, followed 6 hr later by a second intra-arterial bolus (7).
Evidence that vascular endothelial growth factor (VEGF) stimulates angiogenesis in vivo has been developed in experiments performed on rat and rabbit cornea (8,9), the chorioallantoic membrane (10), and the rabbit bone graft model (9). The finding that VEGF could be employed to achieve angiogenesis that was therapeutic was first demonstrated by Takeshita et al. (4) . The 165 amino acid isoform of VEGF (VEGF165) was administered as a single intraarterial bolus to the internal iliac artery of rabbits in which the ipsilateral femoral artery was excised to induce unilateral hindlimb ischemia. The severity of hindlimb ischemia in this animal model has been shown in previous studies to include reduced TcO2 (5), increased femoral venous lactate (11), and skeletal muscle necrosis (5). Doses of 500-1000 Aig of VEGF produced statistically significant augmentation of angiographically visible collateral vessels, and histologically identifiable capillaries; consequent amelioration of the hemodynamic deficit in the ischemic limb was significantly greater in animals receiving VEGF than in nontreated controls (calf blood pressure ratio = 0.75 ± 0.14 versus 0.48 ± 0.19, p < 0.05). Serial (baseline, as well as 10 and 30 days post-VEGF) angiograms disclosed progressive linear extension of the collateral artery of origin (stem artery) to the distal point of parent-vessel (reentry artery) reconstitution in 7 of 9 VEGFtreated animals. Similar results were achieved in a separate series of experiments in which VEGF was administered by an IM route daily for 10 days (12). By 30 days post-VEGF165, flow at rest, as well as maximum flow velocity and maximum blood flow provoked by 2 mg papaverine, were all significantly higher in the VEGFtreated group (13). These findings thus established proof of principle for the concept that the angiogenic activity of VEGF is sufficiently potent to achieve therapeutic benefit. There is now abundant data in animal models to support the potential utility of recombinant protein therapy in myocardial angiogenesis (7, (14) (15) (16) (17) (18) (19) (20) The relevance of these findings in the rabbit ischemic hindlimb model is supported by recent clinical applications of gene therapy (34). Critical limb ischemia is estimated to develop in approximately 500-1000 individuals per million per year (35) . In a considerable proportion of these patients, the anatomic extent and distribution of arterial occlusive disease is unsuitable for operative or percutaneous revascularization and is thus frequently followed by an inexorable downhill course (36, 37) . No pharmacological treatment has been shown to favorably affect the natural history of critical limb ischemia (38) . Indeed, amputation, despite its associated morbidity, mortality, and functional implications (35, (39) (40) (41) , is often recommended as a solution to the disabling symptoms-particularly excruciating ischemic rest pain-of critical limb ischemia (42) (43) (44) (45) . We first investigated the feasibility of arterial gene transfer of VEGF in patients with critical limb ischemia. Using a dose-escalating design, treatment was initiated with 100 ,ug of phVEGF. Three patients presenting with rest pain (but no gangrene) and treated with 1000 Ag were subsequently shown at 1-year follow-up to have improved blood flow to the ischemic limb and they remain free of rest pain. With the increase in dose of phVEGF165 to 2000 jig, angiographic ( Fig. 1 ) and histologic evidence of new blood vessel formation became apparent (46) . More recently, the use of intramuscular gene transfer, employed initially as a means of treating patients in whom vascular disease in the ischemic limb was too extensive to permit an intraarterial approach, resulted in marked improvement in collateral vessel development in patients with critical limb ischemia (47) . Gene transfer was performed in ten limbs of nine patients with nonhealing ischemic ulcers (n = 7/10) and/or rest pain (n = 10/10) due to peripheral arterial disease. A total dose of 4000 ,ug of naked plasmid DNA encoding the 165 amino acid isoform of human vascular endothelial growth factor (phVEGF165) was injected directly into the muscles of the ischemic limb. Gene expression was documented by a transient increase in serum levels of VEGF monitored by ELISA assay (75) . In a classic experiment performed in the rat cornea, Sholley et al. (76) showed that vascular sprouting could be induced and continue for more than 2 days, despite irradiation treatment sufficient to suppress DNA synthesis. Angiogenic activity in this model was thus interpreted to reflect the dominant impact of EC migration. Similar implications resulted from recent experiments performed with growth factors that were shown to have a preponderant effect on endothelial cell migration, as opposed to proliferation. A recent member of the vascular endothelial family of growth factors, VEGF-C, was initially thought be a specific ligand for lymphatic endothelium. This was based on the fact that overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic vessel hyperplasia without any evidence of angiogenesis (77) . We recently evaluated the bioactivity of VEGF-C (78) by performing proliferation and migration assays on different EC types in vitro. We observed clear mitogenic and chemotactic responses of ECs to VEGF-C, in agreement with previous reports (79, 80) . While the impact on cell migration was similar for VEGF-A and VEGF-C, the proliferative response to VEGF-C was less than that observed for VEGF-A, particularly in the case of human umbilical vein endothelial cells (HUVECs). In spite of the latter, in vivo angiogenesis observed in response to VEGF-C administration in a rabbit ischemic hindlimb model was robust and indistinguishable from that observed previously in the same animal model using VEGF-A recombinant protein (4) or plasmid DNA (32). Similarly, Angiopoietin-1, the recently discovered ligand for the Tie2 receptor, was shown to be chemotactic for endothelial cells but exhibited no proliferative effect in vitro (81) . Nevertheless, using the mouse cornea model (82) , and in a rabbit ischemic hindlimb model (83), we have demonstrated that this growth factor has angiogenic properties in vivo. The fact that the in vivo results of these experiments better parallel in vitro analyses of migra- (Flk-1 cell isolation was used for selection of EC progenitors because of a lack of a suitable anti-mouse CD34 antibody.) Cells overexpressing 1-gal (arrows) have been incorporated into capillaries and small arteries; these cells were identified as ECs by anti-CD31 and anti-BS-1 lectin. (N, 0) Sections of muscles harvested from rabbit ischemic hindlimb 4 weeks after administration of autologous MBCD34+. tion as opposed to proliferation is consistent with notions regarding the relative contribution of these activities to angiogenesis.
Vasculogenesis
Postnatal neovascularization has been previously considered to result exclusively from the proliferation, migration, and remodeling of fully differentiated ECs derived from pre-existing blood vessels, i.e., angiogenesis (60, 84, 85) . The formation of blood vessels from EC progenitors, or angioblasts-i.e., vasculogenesis-has been considered restricted to embryogenesis (86, 87) . We reasoned, however, that the use of hematopoietic stem cells (HSCs) derived from peripheral blood in lieu of bone marrow to provide sustained hematopoietic recovery constituted inferential evidence for circulating stem cells (88) . Given the common ancestry of HSCs and angioblasts, we investigated the hypothesis that stem cells circulating in peripheral blood might under selected circumstances differentiate into ECs (89, 90) . Flk-1 and a second antigen, CD-34, shared by angioblasts and HSCs (91) (92) (93) (94) (95) (96) (97) (98) (99) (100) (101) (102) were used to isolate putative angioblasts from the leukocyte fraction of peripheral blood. In vitro, these cells differentiated into ECs. In animal models of ischemia, heterologous, homologous, and autologous EC progenitors incorporated into sites of active angiogenesis (Fig. 3) . These findings thus suggest that circulating EC progenitors may contribute to neoangiogenesis in adult species, consistent with vasculogenesis.
Parenthetically, these findings may have implications for augmenting collateral vessel growth to ischemic tissues (therapeutic vasculogenesis) and for delivery of pro-angiogenic agents to sites of pathologic or utilitarian angiogenesis. A potentially limiting factor in strategies designed to promote neovascularization of ischemic tissues (46) is the resident population of ECs that is competent to respond to administered angiogenic cytokines. This issue may be successfully addressed with autologous EC transplants. The fact that progenitor ECs home to foci of angiogenesis suggests potential utility as autologous vectors for gene therapy. For treatment of regional ischemia, angiogenesis could be amplified by transfection of CD34+ mononuclear peripheral blood cells to achieve constitutive expression of angiogenic cytokines and/or provisional matrix proteins (103) .
Conclusions
The proof of principle has now been established that therapeutic angiogenesis can be achieved in animal models of myocardial and hind limb ischemia. Moreover, recent clinical studies suggest that patients with severe forms of ischemic vascular disease could potentially benefit from such therapies. The advent of therapeutic angiogenesis has generated controversy with regard to protein versus gene therapy. Resolution of this issue will almost certainly require the empirical experience of human clinical trials. Recombinant FGF and VEGF are now being investigated in human clinical trials for patients with lower-extremity vascular disease and myocardial ischemia, so the magnitude of bioactivity that can be achieved with either of these should be ultimately clarified. Our understanding of postnatal neovascularization is in constant evolution. The discovery of new angiogenic growth factors (VEGF-C, Angiopoietin), and new conceptual mechanisms of neovessel formation (postnatal vasculogenesis), will directly influence the development of new therapeutic strategies to promote neovascularization in ischemic vascular diseases. 
